Montelukast and safety

Following a Government request, the TGA is undertaking additional risk mitigation activities after a new safety review of montelukast In February 2018, mainstream media reported on adverse events allegedly linked to the asthma and hayfever medicine, including the account of the mother of an 18-year-old who died by suicide in 2017. After these reports were

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacists ‘intimidated’ out of pursuing claims
Next The week in review